<SEC-DOCUMENT>0001299933-11-002833.txt : 20110921
<SEC-HEADER>0001299933-11-002833.hdr.sgml : 20110921
<ACCEPTANCE-DATETIME>20110920190619
ACCESSION NUMBER:		0001299933-11-002833
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20110915
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20110921
DATE AS OF CHANGE:		20110920

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Lifevantage Corp
		CENTRAL INDEX KEY:			0000849146
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				841097796
		STATE OF INCORPORATION:			CO
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-30489
		FILM NUMBER:		111100347

	BUSINESS ADDRESS:	
		STREET 1:		11545 WEST BERNARDO COURT
		STREET 2:		SUITE 301
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92127
		BUSINESS PHONE:		858-312-8000

	MAIL ADDRESS:	
		STREET 1:		11545 WEST BERNARDO COURT
		STREET 2:		SUITE 301
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92127

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	LIFELINE THERAPEUTICS, INC.
		DATE OF NAME CHANGE:	20041019

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	YAAK RIVER RESOURCES INC
		DATE OF NAME CHANGE:	19920703

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ANDRAPLEX CORP
		DATE OF NAME CHANGE:	19920406
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>htm_43006.htm
<DESCRIPTION>LIVE FILING
<TEXT>
<!-- CoverPageHeader start -->
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 3.2//EN">
<HTML>
<HEAD>
<TITLE> Lifevantage Corporation (Form: 8-K) </TITLE>
</HEAD>
<BODY TEXT="#000000" BGCOLOR="#FFFFFF" ALINK="#0000FF" HLINK="#FF0000" VLINK="#800080">
<!-- Comment1 -->
<A NAME="DOCUMENT_TOP">&nbsp;</A>
<P>
<!-- CoverPageHeader end --><!-- CoverPageTitle START -->
<A NAME="DOCUMENT_TOP">&nbsp;</A>
<HR NOSHADE>
<P>
<P ALIGN="CENTER">
<FONT SIZE="4">
		UNITED STATES<BR>
	SECURITIES AND EXCHANGE COMMISSION
</FONT>
<BR>
<FONT SIZE="2">
	WASHINGTON, D.C. 20549
</FONT>
<P ALIGN="CENTER">
<FONT SIZE="5">
	FORM 8-K
</FONT>
<FONT SIZE="2">

</FONT>
</P>
<P ALIGN="CENTER">
<FONT SIZE="3">
	CURRENT REPORT
</FONT>
</P>
<P ALIGN="CENTER">
<FONT SIZE="2">
	Pursuant to Section&nbsp;13 or 15(d) of the Securities Exchange Act of 1934
</FONT>
</P>
<CENTER>
<TABLE CELLSPACING="0" BORDER="0" CELLPADDING="0" WIDTH="100%">
<TR VALIGN="BOTTOM">
<TD WIDTH="51%">
	&nbsp;
</TD>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="44%">
	&nbsp;
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	Date of Report (Date of Earliest Event Reported):
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	September 15, 2011
</FONT>
</TD>
</TR>
</TABLE>
<BR>
</CENTER>
<!-- CoverPageTitle END --><!-- CoverPageRegistrant START -->
<P ALIGN="CENTER"><!-- -->
<FONT SIZE="6">
	Lifevantage Corporation
</FONT>
<FONT SIZE="2">
<BR>__________________________________________<BR>
	(Exact name of registrant as specified in its charter)
</FONT>
<CENTER>
<TABLE CELLSPACING="0" BORDER="0" CELLPADDING="0" WIDTH="100%">
<TR VALIGN="BOTTOM">
<TD WIDTH="33%">
	&nbsp;
</TD>
<TD WIDTH="34%">
	&nbsp;
</TD>
<TD WIDTH="33%">
	&nbsp;
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	Colorado
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	000-30489
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	90-0224471
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
_____________________<BR>
	(State or other jurisdiction
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
_____________<BR>
	(Commission
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
______________<BR>
	(I.R.S. Employer
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	of incorporation)
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	File Number)
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	Identification No.)
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	11545 W. Bernardo Court, Suite 301, San Diego, California
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	92127
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
_________________________________<BR>
	(Address of principal executive offices)
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
___________<BR>
	(Zip Code)
</FONT>
</TD>
</TR>
</TABLE>
</CENTER>
<CENTER>
<TABLE CELLSPACING="0" BORDER="0" CELLPADDING="0" WIDTH="100%">

<TR VALIGN="BOTTOM">
<TD WIDTH="51%">
	&nbsp;
</TD>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="44%">
	&nbsp;
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	Registrant&#146;s telephone number, including area code:
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	858-312-8000
</FONT>
</TD>
</TR>
</TABLE>
</CENTER>
<P ALIGN="CENTER">
<FONT SIZE="2">
	Not Applicable
<BR>______________________________________________<BR>
	Former name or former address, if changed since last report
</FONT>
<P ALIGN="CENTER">
<FONT SIZE="2">
	&nbsp;
</FONT>
<!-- CoverPageRegistrant END --><P><FONT SIZE="2">
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any
of the following provisions:</FONT>
</P>
<P><FONT SIZE="2">
[&nbsp;&nbsp;]&nbsp;&nbsp;Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)<br>
[&nbsp;&nbsp;]&nbsp;&nbsp;Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)<br>
[&nbsp;&nbsp;]&nbsp;&nbsp;Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))<br>
[&nbsp;&nbsp;]&nbsp;&nbsp;Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))<br>
</P></FONT><!-- PageBreak START -->
<P>
<HR NOSHADE>
<DIV ALIGN="LEFT" STYLE="PAGE-BREAK-BEFORE:ALWAYS">
<A HREF="#DOCUMENT_TOP">
<U>
<B>
<FONT SIZE="2">Top of the Form</FONT>
</B>
</U>
</A>
</DIV>
<!-- PageBreak END --><!-- Item START -->
<P ALIGN="LEFT">
<FONT SIZE="2">
<B>
	Item 1.01 Entry into a Material Definitive Agreement.
</B>
</FONT>
</P>
<P ALIGN="LEFT">
<FONT SIZE="2">
On September 15, 2011, we entered into an agreement with Donny Osmond Concerts, Inc. ("DOC").  The agreement has an effective date of September 1, 2011.  Under the agreement, Donny Osmond will act as a spokesperson for our company and with respect to our products, including Protandim.  In exchange, we have agreed to pay DOC certain fees for Mr. Osmond's various promotional appearances and video recordings and commissions for certain sales of Protandim and the Company's Vantage Pack.  <br><br>The agreement will terminate two years following its effective date, unless earlier terminated in accordance with the agreement.<br><br>The foregoing summary of the terms of the agreement with DOC is qualified in its entirety by reference to the agreement, which will be filed as an exhibit to our periodic report for the current period.<br>
</FONT>
</P>
<!-- Item END -->
<BR><BR><BR><BR><!-- Item START -->
<P ALIGN="LEFT">
<FONT SIZE="2">
<B>
	Item 8.01 Other Events.
</B>
</FONT>
</P>
<P ALIGN="LEFT">
<FONT SIZE="2">
LifeVantage Corporation ("LifeVantage," the "Company" "we" or "us") has scheduled its fiscal year 2012 Annual Meeting of Shareholders (the "FY 2012 Annual Meeting") to be held at the Company's offices in South Jordan, Utah on January 10, 2012.  The record date for shareholders entitled to receive notice of and to vote at the FY 2012 Annual Meeting will be November 11, 2011.  <br><br>Advance Notice Deadline for Rule 14a-8 Shareholder Proposals<br><br>Because the date of the FY 2012 Annual Meeting is more than 30 days after the anniversary of the Fiscal year 2011 annual meeting of the Company's shareholders, in accordance with Rule 14a-8 under the Securities Exchange Act of 1934, shareholders must deliver written notice of such proposals for inclusion in the Company's proxy statement relating to such meeting no later than the close of business on October 3, 2011 to LifeVantage Corporation, Attention: Corporate Secretary at 11545 W. Bernardo Court, Suite 301, San Diego, California 92127.  Rule 14a-8 proposals must also comply with the requirements of Rule 14a-8 and other applicable law, or otherwise may be omitted from the Company's proxy statement.<br><br>Advance Notice Deadline for Director Nominations and Other Shareholder Proposals<br><br>In accordance with the Company's bylaws, if a shareholder wishes to present a proposal, including a director nomination, at our FY 2012 Annual Meeting and the proposal is not intended to be included in our proxy statement relating to that meeting, the shareholder must give advance notice in writing to LifeVantage Corporation, Attention: Corporate Secretary at 11545 W. Bernardo Court, Suite 301, San Diego, California 92127 no later than the close of business on October 3, 2011. If a shareholder fails to give timely notice of a proposal, the shareholder will not be permitted to present the proposal to the shareholders for a vote at our FY 2012 Annual Meeting.  In addition, our bylaws include other requirements for the submission of proposals and the nomination of candidates for director.<br>
</FONT>
</P>
<!-- Item END -->
<BR><BR><BR><BR><!-- Item START -->
<P ALIGN="LEFT">
<FONT SIZE="2">
<B>
	Item 9.01 Financial Statements and Exhibits.
</B>
</FONT>
</P>
<P ALIGN="LEFT">
<FONT SIZE="2">
Exhibit No.		Description<br>99.1		        Press Release Dated September 20, 2011<br>
</FONT>
</P>
<!-- Item END -->
<BR><BR><BR><BR><P ALIGN="LEFT" STYLE="FONT-SIZE: 10PT"></P><!-- PageBreak START -->
<P>
<HR NOSHADE>
<DIV ALIGN="LEFT" STYLE="PAGE-BREAK-BEFORE:ALWAYS">
<A HREF="#DOCUMENT_TOP">
<U>
<B>
<FONT SIZE="2">Top of the Form</FONT>
</B>
</U>
</A>
</DIV>
<!-- PageBreak END --><!-- SignatureHeader START -->
<P ALIGN="CENTER">
<FONT SIZE="2">
<B>
	SIGNATURES
</B>
</FONT>
</P>
<P ALIGN="LEFT">
<FONT SIZE="2">
	Pursuant to the requirements of the Securities Exchange Act of 1934, the
	registrant has duly caused this report to be signed on its behalf by the
	undersigned hereunto duly authorized.
</FONT>
</P>
<!-- SignatureHeader END --><!-- Signature START -->
<CENTER>
<TABLE CELLSPACING="0" BORDER="0" CELLPADDING="0" WIDTH="100%">
<TR VALIGN="BOTTOM">
<TD WIDTH="19%">
	&nbsp;
</TD>
<TD WIDTH="34%">
	&nbsp;
</TD>
<TD WIDTH="3%">
	&nbsp;
</TD>
<TD WIDTH="1%">
	&nbsp;
</TD>
<TD WIDTH="43%">
	&nbsp;
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="3" VALIGN="TOP" ALIGN="LEFT">
<FONT SIZE="2">
	Lifevantage Corporation
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP">
<FONT SIZE="2">
<I>
	September 20, 2011
</I>
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT SIZE="2">
<I>
	By:
</I>
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT SIZE="2">
<I>
	/s/ Carrie E. McQueen
</I>
<BR>
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<HR SIZE="1" NOSHADE>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT SIZE="2">
<I>
	Name: Carrie E. McQueen
</I>
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT SIZE="2">
<I>
	Title: Chief Financial Officer
</I>
</FONT>
</TD>
</TR>
</TABLE>
</CENTER>
<!-- Signature END --><!-- PageBreak START -->
<P>
<HR NOSHADE>
<DIV ALIGN="LEFT" STYLE="PAGE-BREAK-BEFORE:ALWAYS">
<A HREF="#DOCUMENT_TOP">
<U>
<B>
<FONT SIZE="2">Top of the Form</FONT>
</B>
</U>
</A>
</DIV>
<!-- PageBreak END --><P ALIGN="CENTER">
<FONT SIZE="2">
	Exhibit&nbsp;Index
</FONT>
<CENTER>
<TABLE CELLSPACING="0" BORDER="0" CELLPADDING="0" WIDTH="60%">
<TR VALIGN="BOTTOM">
<TD WIDTH="8%">
	&nbsp;
</TD>
<TD WIDTH="15%">
	&nbsp;
</TD>
<TD WIDTH="77%">
	&nbsp;
</TD>
</TR>

<BR>
<TR VALIGN="BOTTOM">
<TD NOWRAP ALIGN="LEFT">
<FONT SIZE="1">
<B>
	Exhibit No.
</B>
</FONT>
</TD>
<TD>
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP ALIGN="LEFT">
<FONT SIZE="1">
<B>
	Description
</B>
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD NOWRAP ALIGN="CENTER">
<HR SIZE="1" NOSHADE>
</TD>
<TD>
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP ALIGN="CENTER">
<HR ALIGN="LEFT" SIZE="1" WIDTH="88%" NOSHADE>
</TD>
</TR>





<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" WIDTH="8%" nowrap>
<FONT SIZE="2">
<DIV ALIGN="LEFT">
	99.1
</DIV>
</FONT>
</TD>
<TD WIDTH="15%">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP" WIDTH="77%">
<FONT SIZE="2">
Press Release Dated September 20, 2011
</FONT>
</TD>
</TR></TABLE></CENTER><!-- HTMLFooter START -->
</BODY>
</HTML>
<!-- HTMLFooter END -->
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exhibit1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 3.2//EN">
<HTML>
<HEAD>
<TITLE> EX-99.1 </TITLE>
</HEAD>
<BODY TEXT="#000000" BGCOLOR="#FFFFFF" ALINK="#0000FF" HLINK="#FF0000" VLINK="#800080">

<BODY style="font-family: 'Times New Roman',Times,serif">


<P align="center" style="font-size: 10pt"><FONT style="font-size: 14pt"><B>LifeVantage Announces That Donny Osmond Has Teamed With The Company As A Spokesperson for<BR>
Protandim</B><sup><B>&#174;</B></sup><B>, The Nrf2 Synergizer</B></FONT>



<P align="center" style="font-size: 14pt"><FONT style="font-size: 12pt"><B>Osmond Teams With Company After Taking Protandim At His Doctor&#146;s Suggestion And Experiencing<BR>
Significant Health Benefits</B></FONT>



<P align="left" style="font-size: 12pt"><FONT style="font-size: 11pt"><B>Salt Lake City, UT, September&nbsp;20, 2011</B>, LifeVantage Corporation (OTCBB: LFVN), maker of
Protandim&#174;, the Nrf2 Synergizer&#153; patented dietary supplement, today announced that legendary
entertainer Donny Osmond, popular among all generations and whose career spans over five decades,
is now acting as spokesperson for the Company&#146;s flagship product, Protandim.
</FONT>

<P align="left" style="font-size: 11pt">Donny Osmond is famous for his music as well as his youthful appearance. Starring in one of the
most popular Las Vegas shows, &#147;Donny & Marie,&#148; and the oldest celebrity ever to win <I>Dancing With
The Stars, </I>Osmond credits his youthful appearance to his dedication to healthy living, taking an
active role in physical fitness and caring for himself. As part of his health regimen, Mr.&nbsp;Osmond
has been taking Protandim for approximately two years at his doctor&#146;s recommendation and has
experienced personal success with the supplement.


<P align="left" style="font-size: 11pt">&#147;I take Protandim daily,&#148; Osmond said. &#147;I&#146;m often asked to endorse products, but Protandim is the
rare product I&#146;ve chosen to share with others because I&#146;ve experienced many health benefits and
anti-aging results which I attribute to Protandim.&#148;


<P align="left" style="font-size: 11pt">Donny was introduced to LifeVantage and Protandim, the Nrf2 Synergizer, in 2009, and had his doctor
review the dietary supplement before taking it. Donny was then informed through his doctor that
Protandim reduces oxidative stress and activates Nrf2, which up-regulates positive genes that are
often called survival genes, and down-regulates negative factors, such as inflammation.&#148;


<P align="left" style="font-size: 11pt">To this, Osmond said, &#147;I believe Protandim is one of the reasons I look and feel as young as I do,
so I&#146;m eager to share the message about it with others.&#148;


<P align="left" style="font-size: 11pt">&#147;This is a great opportunity to get Protandim back on the national stage and to attract
widespread media and consumer attention just as we did when Protandim was featured on ABC
Primetime,&#148; said David W. Brown, President of LifeVantage Network. &#147;We&#146;re extremely pleased Donny
Osmond has joined LifeVantage as a spokesperson for our product. His frequent public appearances,
combined with his popularity among all generations, make him the perfect voice for LifeVantage.&#148;


<P align="left" style="font-size: 11pt">Douglas C. Robinson, LifeVantage Chief Executive Officer, added, &#147;Our relationship with Donny
Osmond is a significant step for our Company. Donny Osmond was acting as an informed consumer when
he first took our product to his doctor who studied it and validated it and then recommended it to
Donny. His personal experience, together with his celebrity status, should enable him to tell the
world why activating Nrf2 and reducing oxidative stress, linked to numerous health conditions, is
important.&#148;


<P align="left" style="font-size: 11pt"><B>About Donny Osmond</B>


<P align="left" style="font-size: 11pt">Donny Osmond&#146;s career in radio, television, film, singing, songwriting and performing on the
Broadway stage has spanned more than five decades. Host of a worldwide syndicated daily radio show,
he anchors entertainment reports on <I>Good Morning America, </I>special reports for <I>Entertainment Tonight</I>
and is the 2009 <I>Dancing With The Stars </I>(37&nbsp;million viewers weekly) champion. In addition to
starring with his sister, Marie, in the Donny & Marie Show at the Flamingo Hotel & Casino on the
Las Vegas Strip, now in its fourth year, he and his sister recently released their first CD
together in 30&nbsp;years, &#147;Donny & Marie,&#148; which debuted at number 30 on the Billboard 200 Pop Albums
chart and at number 7 on the country chart. Donny has over 150,000 followers on social media, with
more joining every month. Donny and Debbie, his wife of 31&nbsp;years, have five children and three
grandchildren. For more information about Donny, visit <U>www.donny.com</U>.


<P align="left" style="font-size: 11pt"><B>About Protandim, the Nrf2 Synergizer</B>


<P align="left" style="font-size: 11pt">Protandim&#174; is a clinically demonstrated supplement that provides substantial benefits for healthy
aging. This patented Nrf2-activating therapy works in a very different way than conventional
antioxidant supplements. Unlike vitamin- or carotenoid-containing products that have proven to be
largely ineffective in reducing oxidative stress caused by free radicals, Protandim&#174; is an indirect
antioxidant therapy, which stimulates the body&#146;s production of its own powerful antioxidant enzymes
and other stress-related gene products. Protandim&#174; works at the cellular level, triggering cells to
naturally increase production of protective antioxidant enzymes such as superoxide dismutase (SOD),
catalase, and glutathione synthase, while decreasing production of pro-inflammatory signals.


<P align="left" style="font-size: 11pt">A peer-reviewed human clinical study showed that after Protandim&#174; was taken for 30 consecutive
days, important biochemical markers of aging were decreased by an average of 40%. The study also
reported that these markers of aging were reduced in the subjects taking Protandim&#174; to the level of
a typical 20&nbsp;year old. Protandim&#174; is currently the subject of approximately 20 scientific studies
at universities and research facilities. The nature and stages of the studies vary.


<P align="left" style="font-size: 11pt">Under the Dietary Supplement Health and Education Act, Protandim&#174; is considered a &#147;dietary
supplement&#148;. Protandim&#174; is not intended for the prevention, diagnosis, treatment, mitigation or
cure of any disease. For more information about Protandim&#174;, visit
<U>www.LifeVantage.com</FONT><FONT style="font-size: 12pt">.</U>
</FONT>

<P align="left" style="font-size: 12pt"><FONT style="font-size: 11pt"><B>About LifeVantage Corporation</B>
</FONT>

<P align="left" style="font-size: 11pt">LifeVantage<sup>&#174;</sup>, (OTCBB: LFVN), maker of Protandim<sup>&#174;</sup>, the Nrf2 Synergizer
patented dietary supplement, is a science based nutraceutical company. LifeVantage is dedicated to
visionary science that promises to transform wellness and anti-aging internally and externally with
supplements that reduce oxidative stress at the cellular level. The Company was founded in 2003 and
currently has offices in Salt Lake City, UT, and San Diego, CA. For more information, visit
<U>www.LifeVantage.com</U>.


<P align="left" style="font-size: 11pt"><B>Forward Looking Statements</B>


<P align="left" style="font-size: 11pt">This document contains forward-looking statements made pursuant to the safe harbor provisions of
the Private Securities Litigation Reform Act of 1995. Words and expressions reflecting confidence,
optimism, satisfaction or disappointment with current prospects, as well as words such as
&#147;believe,&#148; &#147;hopes,&#148; &#147;intends,&#148; &#147;estimates,&#148; &#147;expects,&#148; &#147;projects,&#148; &#147;plans,&#148; &#147;anticipates, and
variations thereof, identify forward-looking statements, but their absence does not mean that a
statement is not forward-looking. Such forward-looking statements are not guarantees of performance
and the Company&#146;s actual results could differ materially from those contained in such statements.
These forward-looking statements are based on the Company&#146;s current expectations and beliefs
concerning future events affecting the Company and involve known and unknown risks and
uncertainties that may cause the Company&#146;s actually results or outcomes to be materially different
from those anticipated and discussed herein. These risks and uncertainties include, among others,
the potential failure or unintended negative consequences of the implementation of the Company&#146;s
network marketing sales channel; the Company&#146;s ability to retain independent distributors or to
attract new independent distributors on an ongoing basis; the potential for third party and
governmental actions involving the Company&#146;s network marketing sales channel; the potential for
product liability claims against the Company; the risk government regulators and regulations could
adversely affect the Company&#146;s business; future laws or regulations may hinder or prohibit the
production or sale of the Company&#146;s existing product and future products; unfavorable publicity
could materially hurt the Company&#146;s business; and the Company&#146;s ability to protect its intellectual
property rights and the value of its product. These and other risk factors are discussed in greater
detail in the Company&#146;s Annual Report on Form 10-K and its Quarterly Report on Form 10-Q under the
caption &#147;Risk Factors,&#148; and in other documents filed by the Company from time to time with the
Securities and Exchange Commission. The Company cautions investors not to place undue reliance on
the forward-looking statements contained in this document. All forward-looking statements are based
on information currently available to the Company on the date hereof, and the Company undertakes no
obligation to revise or update these forward-looking statements to reflect events or circumstances
after the date of this document, except as required by law.


<P align="left" style="font-size: 11pt; text-indent: 20%">###


<P align="left" style="font-size: 11pt">Media Relations Contact:
<BR>
Andrea Ramsey (801)&nbsp;432-9019


<P align="left" style="font-size: 11pt">Investor Relations Contact:
<BR>
Cindy England (801)&nbsp;432-9036
<BR>
-or-
<BR>
John Mills (310)&nbsp;954-1105
<BR>
Senior Managing Director, ICR, LLC


<P align="left" style="font-size: 11pt">SOURCE LifeVantage Corporation



<P align="center" style="font-size: 10pt; display: none">




<!-- v.121908 -->
</BODY>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
